DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
Cambodia King Pardons Opposition Leader Kem Sokha After Treason Conviction 
US Stock Futures Jump on Reports of Preliminary US-Iran Peace Deal Despite Fed’s Hawkish Outlook 
Japan Trade Deficit Narrows as Exports Surge in May 
Florida Supreme Court Allows GOP Congressional Map to Stand Ahead of 2026 Midterm Elections 
Oil Prices Ease as Markets Weigh U.S.-Iran Peace Deal and Strait of Hormuz Reopening 
Sable Offshore Wins Key Court Battle Over California Oil Pipeline 
Oil Prices Recover Slightly as U.S. Crude Inventories Fall, But Iran Deal Caps Gains 
U.S. Reinstates Sanctions on U.N. Expert Francesca Albanese Amid Legal Battle 
German Auto Suppliers Turn Bearish as Investment and Jobs Shift Overseas 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Oil Prices Drop as U.S.-Iran Peace Deal Eases Supply Concerns 
Detroit’s high property taxes are driving a housing affordability crisis – how can city leaders bring down costs? 
US Appeals Court Allows Trump Military Enlistment Ban on Transgender Recruits, Protects Current Service Members 
Trump Administration Urges Judge to Allow UFC Event on White House Lawn 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
